MARKET

ACXP

ACXP

Acurx Pharmaceuticals Inc
NASDAQ
1.540
+0.080
+5.48%
After Hours: 1.550 +0.01 +0.65% 19:49 08/07 EDT
OPEN
1.470
PREV CLOSE
1.460
HIGH
1.600
LOW
1.450
VOLUME
113.32K
TURNOVER
--
52 WEEK HIGH
8.34
52 WEEK LOW
1.326
MARKET CAP
6.62M
P/E (TTM)
-0.3454
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Acurx Pharmaceuticals (ACXP)
TipRanks · 6d ago
Acurx Pharmaceuticals Announces Intent For Further Discussion With FDA Regarding Ibezapolstat's Phase 3 Clinical Program, Scope Of Its Planned NDA
Benzinga · 6d ago
Acurx announces outcome of meeting with FDA on ibezapolstat’s clinical program
TipRanks · 6d ago
Weekly Report: what happened at ACXP last week (0727-0731)?
Weekly Report · 6d ago
Weekly Report: what happened at ACXP last week (0720-0724)?
Weekly Report · 07/27 10:23
Weekly Report: what happened at ACXP last week (0713-0717)?
Weekly Report · 07/20 10:20
Acurx’s ibezapolstat shows microbe preservation efficacy
TipRanks · 07/14 12:10
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
PR Newswire · 07/14 12:00
More
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Webull offers Acurx Pharmaceuticals Inc stock information, including NASDAQ: ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.